Please login to the form below

Not currently logged in
Email:
Password:

Novimmune appoints Guillaume de Sampaïo

He brings experience from Roche, Novartis and Actelion to the Swiss biotech 

Swiss biotech Novimmune has appointed Guillaume de Sampaïo as global head of project management in a role that will also see him sit on its senior management team.

De Sampaïo has 15 years experience in life sciences, having previously served at the likes of Roche, Novartis and Actelion.

Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group.

During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014. 

Novimmune chairman and CEO Eduard Holdener said: “With the progression of our R&D pipeline, project management becomes increasingly a crucial element in supporting our growth strategy. 

“Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead program, NI-0501.”

30th November 2016

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...
Kate Shaw reflects on Innovative Trials' first US office openings
On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening...
Meeting1
Reimagining strategy development for a hybrid workforce
By Janice MacLennan...